CNA landscape of HER2-negative breast cancer during administration of taxane-containing schemes of neoadjuvant chemotherapy ; CNA-ландшафт HER2-негативного рака молочной железы при применении таксансодержащих схем неоадъювантной химиотерапии

Authors: Ibragimova M.K., Kravtsova E.A., Tsyganov M.M., Litviakov N.V.

Contributors: The work was carried out with the financial support of the Russian Science Foundation (grant No. 22-25-00499)., Работа выполнена при финансовой поддержке Российского научного фонда (грант № 22-25-00499).

Source: Advances in Molecular Oncology; Vol 12, No 1 (2025); 53-60 ; Успехи молекулярной онкологии; Vol 12, No 1 (2025); 53-60 ; 2413-3787 ; 2313-805X

Subject Terms: breast cancer, tumor CNA landscape, taxane-containing scheme, neoadjuvant chemotherapy, copy number aberration, outcome prediction, рак молочной железы, CNA-ландшафт опухоли, таксансодержащая схема, неоадъювантная химиотерапия, аберрация числа копий, прогнозирование исхода

File Description: application/pdf

Relation: https://umo.abvpress.ru/jour/article/view/757/381; https://umo.abvpress.ru/jour/article/view/757

Availability: https://umo.abvpress.ru/jour/article/view/757
https://doi.org/10.17650/2313-805X-2025-12-1-53-60

Neoadjuvant chemotherapy for locally advanced oral mucosal cancer ; Неоадъювантная химиотерапия при местно-распространенном раке слизистой оболочки полости рта

Authors: Kropotov M.A., Zharkov O.A., Yakovleva L.P., Vyzhigina B.B., Romano I.S., Likhtenberg E.O.

Source: Head and Neck Tumors; Vol 15, No 3 (2025); 25-34 ; Опухоли головы и шеи; Vol 15, No 3 (2025); 25-34 ; 2411-4634 ; 2222-1468

Subject Terms: neoadjuvant chemotherapy, oral mucosa, squamous cell carcinoma, complex cancer treatment, неоадъювантная химиотерапия, слизистая оболочка полости рта, плоскоклеточный рак, комплексное лечение рака

File Description: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/1099/684; https://ogsh.abvpress.ru/jour/article/view/1099

Availability: https://ogsh.abvpress.ru/jour/article/view/1099
https://doi.org/10.17650/2222-1468-2025-15-3-25-34

Immediate results of neoadjuvant chemotherapy for resectable colon cancer ; Непосредственные результаты неоадъювантной химиотерапии резектабельного рака ободочной кишки

Authors: D. I. Azovsky, S. G. Afanasyev, L. V. Spirina, A. V. Avgustinovich, O. V. Cheremisina, S. V. Vtorushin, Д. И. Азовский, С. Г. Афанасьев, Л. В. Спирина, А. В. Августинович, О. В. Черемисина, С. В. Вторушин

Source: Siberian journal of oncology; Том 24, № 1 (2025); 101-109 ; Сибирский онкологический журнал; Том 24, № 1 (2025); 101-109 ; 2312-3168 ; 1814-4861

Subject Terms: лекарственный патоморфоз, total neoadjuvant chemotherapy, combined treatment, immediate efficacy, toxicity, tumor regression, «тотальная» неоадъювантная химиотерапия, комбинированное лечение, непосредственная эффективность, токсичность

File Description: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/3459/1318; Ferlay J., Ervik M., Lam F., Laversanne M., Colombet M., Mery L., Piñeros M., Znaor A., Soerjomataram I., Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2024. [cited 2024 November 6]. URL: https://gco.iarc.who.int/today.; Состояние онкологической помощи населению России в 2023 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2024. 252 с.; Одинцова И.Н., Черемисина О.В., Писарева Л.Ф., Спивакова И.О., Вусик М.В. Эпидемиология колоректального рака в Томской области. Сибирский онкологический журнал. 2017; 16(4): 89–95. doi:10.21294/1814-4861-2017-16-4-89-95. EDN: ZFDGKP; Хазов А.В., Хрыков Г.Н., Эрдниев С.П., Савчук С.А. Неоадъювантное лечение местнораспространенного рака ободочной кишки (обзор литературы). Вопросы онкологии. 2019; 65(1): 63–68. EDN: ZDEXZJ.; Suenaga M., Fujimoto Y., Matsusaka S., Shinozaki E., Akiyoshi T., Nagayama S., Fukunaga Y., Oya M., Ueno M., Mizunuma N., Yamaguchi T. Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01) Onco Targets Ther. 2015; 8: 1111–8. doi:10.2147/OTT.S83952.; Lerebours F., Rivera S., Mouret-Reynier M.A., Alran S., Venat-BouvetL., Kerbrat P., Salmon R., Becette V., BourgierC., CherelP., BoussionV., Balleyguier C., ThibaultF., Lavau-Denes S., NabholzJ.M., Sigal B., Trassard M., Mathieu M.C., Martin A.L., Lemonnier J., Mouret-Fourme E. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609) Cancer. 2016; 122(19): 3032–40. doi:10.1002/cncr.30143.; Samalin E., Ychou M. Neoadjuvant therapy for gastroesophageal adenocarcinoma. World J Clin Oncol. 2016; 7(3): 284–92. doi:10.5306/wjco.v7.i3.284.; Yoshikawa T., Morita S., Tanabe K., Nishikawa K., Ito Y., Matsui T., Fujitani K., Kimura Y., Fujita J., Aoyama T., Hayashi T.,Cho H., Tsuburaya A., Miyashita Y., Sakamoto J. Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer. Eur J Cancer. 2016; 62: 103–11. doi:10.1016/j.ejca.2016.04.012.; Grothey A., Sobrero A.F., Shields A.F., Yoshino T., Paul J., Taieb J., Souglakos J., Shi Q., Kerr R., Labianca R. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018 Mar 29; 378(13): 1177–1188. doi:10.1056/NEJMoa1713709.; Ludmir E.B., Palta M., Willett C.G., Czito B.G. Total neoadjuvant therapy for rectal cancer:An emerging option. Cancer. 2017 May 1; 123(9): 1497–1506. doi:10.1002/cncr.30600.; Petrelli F., Trevisan F., Cabiddu M., Sgroi G., Bruschieri L., Rausa E., Ghidini M., Turati L. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes.Ann Surg. 2020 Mar; 271(3): 440–448. doi:10.1097/SLA.0000000000003471.; Barrak D., Villano A.M., Moslim M.A., Hopkins S.E., Lefton M.D., Ruth K., Reddy S.S. Total Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma IsAssociated With Limited Lymph Node Yield but Improved Ratio. J Surg Res. 2022; 280: 543–550. doi:10.1016/j.jss.2022.08.002.; Августинович А.В., Афанасьев С.Г., Добродеев А.Ю., Волков М.Ю., Костромицкий Д.Н., Спирина Л.В., Черемисина О.В. Непосредственная эффективность и токсичность тотальной неоадъювантной химиотерапии резектабельного рака желудка. Сибирский онкологический журнал. 2022; 21(1): 11–19. doi:10.21294/1814-4861-2022-21-1-11-19. EDN: AMBMXZ.; Liu S., Jiang T., Xiao L., Yang S., Liu Q., Gao Y., Chen G., Xiao W. Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. Oncologist. 2021 Sep; 26(9): e1555-e1566. doi:10.1002/onco.13824.; Vogel J.D., Felder S.I., Bhama A.R., Hawkins A.T., Langenfeld S.J., Shaffer V.O., Thorsen A.J., Weiser M.R., Chang G.J., LightnerA.L., Feingold D.L., Paquette I.M. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer. Dis Colon Rectum 2022; 65(2): 148–177. doi:10.1097/DCR.0000000000002323.; Argilés G., Tabernero J., Labianca R., Hochhauser D., Salazar R., Iveson T., Laurent-Puig P., Quirke P., Yoshino T., Taieb J., Martinelli E., Arnold D.; ESMO Guidelines Committee. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Oct; 31(10): 1291–1305. doi:10.1016/j.annonc.2020.06.022.; Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012; 13(11): 1152–60. doi:10.1016/S1470-2045(12)70348-0.; Jakobsen A., Andersen F., Fischer A., Jensen L.H., Jørgensen J.C.R., Larsen O., Lindebjerg J., Pløen J., Rafaelsen S.R., Vilandt J. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncol. 2015; 54 (10):1747–53. doi:10.3109/0284186X.2015.1037007.; Arredondo J., Baixauli J., Pastor C., Chopitea A., Sola J.J., González I., A-Cienfuegos J., Martínez P., Rodriguez J., Hernández-Lizoain J.L. Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery. Clin Transl Oncol. 2017; 19(3): 379–385. doi:10.1007/s12094-016-1539-4.; Hu Z., Ding J., Ma Z., Sun R., Seoane J.A., Shaffer J.S., Suarez C.J., Berghoff A.S., Cremolini C., Falcone A., Loupakis F., Birner P., Preusser M., Lenz H.J., Curtis C. Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet. 2019; 51(7): 1113–1122. doi:10.1038/s41588-019-0423-x.; Smith H.G., Chiranth D., Mortensen C.E., Schlesinger N.H. The significance of subdivisions of microscopically positive (R1) margins in colorectal cancer: a retrospective study of a national cancer registry. Colorectal Dis. 2022 Feb; 24(2): 197–209. doi:10.1111/codi.15971.; André T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., Topham C., Zaninelli M., Clingan P., Bridgewater J., Tabah-Fisch I., de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350 (23): 2343–51. doi:10.1056/NEJMoa032709.; Smith H.G., Skovgaards D.M., Bui N.H., Chiranth D., Qvortrup C., Schlesinger N.H. Differences in adjuvant chemotherapy and oncological outcomes according to margin status in patients with stage III colon cancer. Acta Oncol. 2023; 62(6): 594–600. doi:10.1080/0284186X.2023.2218555.; André T., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., Bonetti A., Clingan P., Bridgewater J., Rivera F. de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009 Jul 1; 27(19): 3109–16. doi:10.1200/JCO.2008.20.6771.; Bayraktar U.D., Chen E., Bayraktar S., Sands L.R., Marchetti F., Montero A.J., Rocha-Lima C.M.S. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma? Cancer. 2011; 117(11): 2364–70. doi:10.1002/cncr.25720.; https://www.siboncoj.ru/jour/article/view/3459

Availability: https://www.siboncoj.ru/jour/article/view/3459
https://doi.org/10.21294/1814-4861-2025-24-1-101-109

Three-year results of the Russian multicenter prospective randomized trial RuCort3 ; Трехлетние результаты российского многоцентрового проспективного рандомизированного исследования RuCort3

Authors: A. V. Polynovsky, D. V. Kuzmichev, A. A. Tryakin, M. V. Chernykh, O. A. Kuznetsova, I. A. Karasev, D. V. Aleksantsev, A. M. Karachun, E. V. Tkachenko, E. I. Turyaeva, D. V. Samsonov, I. M. Gridasov, S. E. Prokofiev, Z. Z. Mamedli, А. В. Полыновский, Д. В. Кузьмичев, А. А. Трякин, М. В. Черных, О. А. Кузнецова, И. А. Карасев, Д. В. Алексанцев, А. М. Карачун, Е. В. Ткаченко, Е. И. Тюряева, Д. В. Самсонов, И. М. Гридасов, С. Е. Прокофьев, З. З. Мамедли

Source: Surgery and Oncology; Том 15, № 1 (2025); 18-27 ; Хирургия и онкология; Том 15, № 1 (2025); 18-27 ; 2949-5857

Subject Terms: индукционная/консолидирующая химиотерапия, total neoadjuvant chemotherapy, chemoradiotherapy, induction/consolidation chemotherapy, тотальная неоадъювантная химиотерапия, химиолучевая терапия

File Description: application/pdf

Relation: https://www.onco-surgery.info/jour/article/view/777/490; Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 250 с.; Breugom A.J., van den Broek C.B.M., van Gijn W. et al. The value of adjuvant chemotherapy in rectal cancer patients after preoperative radiotherapy or chemotherapy followed by TMEsurgery: the PROCTOR/SCRIPT study. Eur J Cancer 2013;49:1.; Cionini L., Sainato A., de Paoli A. et al. Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. Radiother Oncol 2010;96:113–4.; Glynne-Jones R., Chau I. Neoadjuvant therapy before surgical treatment. EJC Suppl 2013;11(2):45–59.; Rödel C., Liersch T., Becker H. et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/ AIO-04 randomised phase 3 trial. Lancet Oncol 2012;13:679–87.; Ludmir E.B., Palta M., Willett C.G. et al. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer 2017;123:1497–506. DOI:10.1002/cncr.30600; Franke A.J., Parekh H., Starr J.S. et al. Total neoadjuvant therapy: a shifting paradigm in locally advanced rectal cancer management. Clin Colorectal Cancer 2018;17:1–12.; Bahadoer R.R., Dijkstra E.A., van Etten B. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2020;22(1):29–42. DOI:10.1016/S1470-2045(20)30555-6; Conroy T., Bosset J.-F., Etienne P-L. et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, openlabel, phase 3 trial. Lancet Oncol 2021;22(5):702–15. DOI:10.1016/S1470-2045(21)00079-6; Jin J., Tang Y., Hu C. et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol 2022;40(15):1681–92. DOI:10.1200/JCO.21.01667; Liao C.-K., Kuo Y.-T., Lin Y.-C. et. al. Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer: a systematic review and meta-analysis. Curr Oncol 2022;29(5):3708–27. DOI:10.3390/curroncol29050297; Gabbani M., Giorgi C., Napoli G. et al. Outcomes of locally advanced rectal cancer patients treated with total neoadjuvant treatment: a meta-anaysis of randomized controlled trials. Clin Colorectal Cancer 2022;21(4):297–308. DOI:10.1016/j.clcc.2022.07.005; Petrelli F., Trevisan F., Cabiddu M. et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg 2020;271(3):440–8. DOI:10.1097/SLA.0000000000003471; Liu S., Jiang T., Xiao L. et al. Total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Oncologist 2021;26(9):e1555–e6. DOI:10.1002/onco.13824; Maas M., Nelemans P.J., Valentini V. et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11:835–44.; Habr-Gama A., Perez R.O., Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240(4):711–7. DOI:10.1097/01.sla.0000141194.27992.32; Romesser P.B., Park B.K., Nemirovsky D. et al. Organ preservation and total neoadjuvant therapy for rectal cancer: investigating long course chemoradiation versus short-course radiation therapy. J Clin Oncol 2023;41(4):10. DOI:10.1200/JCO.2023.41.4_suppl.10; Cionini L., Sainato A., de Paoli A. et al. Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. Radiother Oncol 2010;96:S113–4.

Availability: https://www.onco-surgery.info/jour/article/view/777
https://doi.org/10.17650/2949-5857-2025-15-1-18-27

Mechanisms of drug resistance to neoadjuvant chemotherapy in breast cancer ; Механизмы лекарственной устойчивости к неоадъювантной химиотерапии при раке молочной железы

Authors: Aliev K.A., Zyablitskaya E.Y., Makalish T.P., Sorokina L.E., Asanova E.R.

Contributors: The study was financially supported by the Ministry of Education and Science of Russia (State Assignment No FZEG-2023-0009 “Study of the heterogeneity of the tumor microenvironment as a factor in its aggressiveness and resistance to therapy”)., Работа выполнена при финансовой поддержке Минобрнауки России (государственное задание № FZEG-2023-0009 «Изучение гетерогенности микроокружения опухоли как фактора ее агрессивности и резистентности к терапии»).

Source: Advances in Molecular Oncology; Vol 11, No 3 (2024); 103-113 ; Успехи молекулярной онкологии; Vol 11, No 3 (2024); 103-113 ; 2413-3787 ; 2313-805X

Subject Terms: breast cancer, non-adjuvant chemotherapy, drug resistance, tumor microenvironment, рак молочной железы, неоадъювантная химиотерапия, лекарственная устойчивость, микроокружение опухоли

File Description: application/pdf

Relation: https://umo.abvpress.ru/jour/article/view/712/365; https://umo.abvpress.ru/jour/article/view/712

Availability: https://umo.abvpress.ru/jour/article/view/712
https://doi.org/10.17650/2313-805X-2024-11-3-103-113

MR tomographic evaluation of the effectiveness of neoadjuvant chemotherapy for breast cancer based on pharmacokinetic numerical analysis of tumor uptake of paramagnetic contrast in intravenous contrast enhancement ; МР-томографическая оценка эффективности неоадъювантной химиотерапии рака молочной железы по данным вычислительного фармакокинетического анализа поглощения опухолью парамагнетиков при внутривенном контрастном усилении

Authors: W. Yu. Ussov, S. M. Minin, N. A. Nikitin, E. N. Nogina, I. A. Kosarev, E. Kobelev, L. V. Bashkirov, Zh. Zh. Anashbaev, N. A. Tarabanovskaya, V. Yu. Babikov, Na. V. Denisova, A. L. Chernyshova, A. M. Chernyavsky, В. Ю. Усов, С. М. Минин, Н. А. Никитин, Е. Н. Ногина, И. А. Косарев, Е. Кобелев, Л. В. Башкиров, Ж. Ж. Анашбаев, Н. А. Тарабановская, В. Ю. Бабиков, Н. В. Денисова, А. Л. Чернышова, А. М. Чернявский

Contributors: The study was carried out in accordance with the a Government assignment №123030900018-1., Исследование выполнено в соответствии с Государственным заданием № 123030900018-1.

Source: Translational Medicine; Том 11, № 5 (2024); 428-444 ; Трансляционная медицина; Том 11, № 5 (2024); 428-444 ; 2410-5155 ; 2311-4495

Subject Terms: рак молочной железы, constant of contrast transfer from blood to tumor ККр-Оп, dynamic breast MRI with contrast enhancement, kinetics of tumor accumulation of paramagnetic, neoadjuvant chemotherapy (NAChT), кинетика опухолевого накопления парамагнетиков, константа переноса парамагнетика из крови в опухоль ККр-Оп, неоадъювантная химиотерапия

File Description: application/pdf

Relation: https://transmed.almazovcentre.ru/jour/article/view/995/590; Ширшин А.В., Бойков И.В., Малаховский В.Н. и др. Применение методов цифровой обработки для автоматизированной сегментации сердца по данным компьютерной томографии // Известия Российской военно-медицинской академии. 2022; 41:1:49–54. DOI 10.17816/rmmar104344.; Варфоломеев С.Д., Гуревич К.Г. Биокинетика. Практический курс. М.: ФАИР-ПРЕСС, 1999; 720.; Wang W, Lv S, Xun J, et al. Comparison of diffusion kurtosis imaging and dynamic contrast enhanced MRI in prediction of prognostic factors and molecular subtypes in patients with breast cancer. Eur J Radiol. 2022; 154:110392. DOI:10.1016/j.ejrad.2022.110392.; Li X, Rooney WD, Springer CS. A unified magnetic resonance imaging pharmacokinetic theory: intravascular and extracellular contrast reagents. Magn Reson Med. 2005; 54:6: 1351–9. DOI:10.1002/mrm.20684.; Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017; 18:3: e143–e152. DOI:10.1016/S1470-2045(17)30074-8.; Серебрякова С.В., Шумакова Т.А., Сафронова О.Б. и др. Магнитно-резонансная маммография в диагностике внутрипротокового рака in situ (DCIS)// Радиология — практика. 2021; 3:87:41– 61. DOI 10.52560/2713-0118-2021-3-41-61.; Чипига Л.А., Водоватов А.В., Катаева Г.В. и др. Современные подходы к обеспечению качества диагностики в позитронно-эмиссионной томографии. Медицинская физика. 2019; 2:82:78–92.; Ненахова Ю.Н. Лучевые методы диагностики в оценке эффективности неоадъювантной химиотерапии у пациенток раком молочной железы (обзор литературы) // Диагностическая и интервенционная радиология. 2017; 11:1:67–73. DOI:10.25512/DIR.2017.11.1.09.; Ioannidis GS, Maris TG, Nikiforaki K, et al. Investigating the Correlation of Ktrans With SemiQuantitative MRI Parameters Towards More Robust and Reproducible Perfusion Imaging Biomarkers in Three Cancer Types. IEEE J Biomed Health Inform. 2019; 23:5:1855–1862. DOI:10.1109/JBHI.2018.2888979.; Thawani R, Gao L, Mohinani A, et al. Quantitative DCE-MRI prediction of breast cancer recurrence following neoadjuvant chemotherapy: a preliminary study. BMC Med Imaging. 2022; 22:1:182. DOI:10.1186/s12880-022-00908-0.; Усов В.Ю., Ряннель Ю.Э., Попадич С. и др. Возможности однофотонной эмиссионной компьютерной томографии с 99mTc-Технетрилом в диагностике и оценке распространенности рака молочной железы. Медицинская визуализация. 2001; 4(3):74–86.; Усов В.Ю., Ряннель Ю.Э., Медведева А.А. и др. Маммосцинтиграфия с 99mTc-Технетрилом в оценке состояния первичной опухоли при химиотерапии рака молочной железы. Медицинская визуализация. 2002; 5:2: 86–94.; Крживицкий П.И., Новиков С.Н., Канаев С.В. и др. ОФЭКТ-КТ в диагностике метастатического поражения лимфатических узлов у больных раком молочной железы. Вопросы онкологии. 2017; 63:2:261–266.; Семиглазов В.Ф., Горбунова В.А., Тюляндин С.А. Химиотерапия рака молочной железы: современный взгляд на проблему. Медицинский совет. 2017; 6:56–60. DOI 10.21518/2079-701X-2017-6-56-60.; Tudorica A, Oh KY, Chui SY-C, et al. Early Prediction and Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy Using Quantitative DCEMRI. Transl Oncol. 2016; 9:1:8–17. DOI:10.1016/j.tranon.2015.11.016.; Liang X, Chen X, Yang Z, et al. Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer. BMC Cancer. 2022; 22:1:1250. DOI:10.1186/s12885-022-10315-x.; Wang TC, Huang YH, Huang CS, et al. Computeraided diagnosis of breast DCE-MRI using pharmacokinetic model and 3-D morphology analysis. Magn Reson Imaging. 2014; 32:3:197–205. DOI:10.1016/j.mri.2013.12.002.; МРТ с динамическим контрастным усилением в оценке подмышечных лимфатических узлов при раке молочной железы после неоадъювантной химиотерапии. П. Ю. Гришко, А. С. Петрова, А. В. Комяхов, А. В. Мищенко. Сборник научных работ III Петербургского Международного онкологического форума «Белые ночи 2017», Санкт-Петербург, 22–24 июня 2017 года. ФГБУ «НИИ онкологии им. Н. Н. Петрова» Минздрава России. СПб: АННМО «Вопросы онкологии». 2017; 123–124.; https://transmed.almazovcentre.ru/jour/article/view/995

Availability: https://transmed.almazovcentre.ru/jour/article/view/995
https://doi.org/10.18705/2311-4495-2024-11-5-428-444

Pathological complete response of locally advanced triple-negative breast cancer: case report ; Полный патоморфологический регресс местнораспространенного трижды негативного рака молочной железы после неоадъювантной химиотерапии: клинический случай

Authors: V. V. Konstantinova, G. A. Dashyan, R. M. Ahmedov, A. M. Belousov, В. В. Константинова, Г. А. Дашян, Р. М. Ахмедов, А. М. Белоусов

Source: Siberian journal of oncology; Том 23, № 4 (2024); 186-193 ; Сибирский онкологический журнал; Том 23, № 4 (2024); 186-193 ; 2312-3168 ; 1814-4861

Subject Terms: дозоуплотненный режим, triple-negative breast cancer, pathological complete response, neoadjuvant chemotherapy, dose-dense regimen, полный патоморфологический регресс, неоадъювантная химиотерапия

File Description: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/3204/1263; Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–49. doi:10.3322/caac.21660.; Kemppainen L.M., Kemppainen T.T., Reippainen J.A., Salmenniemi S.T., Vuolanto P.H. Use of complementary and alternative medicine in Europe: Health-related and sociodemographic determinants. Scand J Public Health. 2018; 46(4): 448–55. doi:10.1177/1403494817733869.; Sasaki Y., Cheon C., Motoo Y., Jang S., Park S., Ko S.G., Jang B.H., Hwang D.S. [Complementary and Alternative Medicine for Breast Cancer Patients: An Overview of Systematic Reviews]. Yakugaku Zasshi. 2019; 139(7): 1027–46. Japanese. doi:10.1248/yakushi.18-00215.; Guay E., Cordeiro E., Roberts A. Young Women with Breast Cancer: Chemotherapy or Surgery First? An Evaluation of Time to Treatment for Invasive Breast Cancer. Ann Surg Oncol. 2022; 29(4): 2254–60. doi:10.1245/s10434-021-11102-x.; Polverini A.C., Nelson R.A., Marcinkowski E., Jones V.C., Lai L., Mortimer J.E., Taylor L., Vito C., Yim J., Kruper L. Time to Treatment: Measuring Quality Breast Cancer Care. Ann Surg Oncol. 2016; 23(10): 3392–402. doi:10.1245/s10434-016-5486-7.; Livingston-Rosanoff D., Hanlon B., Marka N., Vande Walle K., Stankowski-Drengler T., Schumacher J., Greenberg C.C., Neuman H., Wilke L.G. Time to initiation of neo-adjuvant chemotherapy for breast cancer treatment does not influence patient survival: A study of US breast cancer patients. Breast J. 2020; 26(4): 625–9. doi:10.1111/tbj.13625.; Riley D.S., Barber M.S., Kienle G.S., Aronson J.K., von Schoen-Angerer T., Tugwell P., Kiene H., Helfand M., Altman D.G., Sox H., Werthmann P.G., Moher D., Rison R.A., Shamseer L., Koch C.A., Sun G.H., Hanaway P., Sudak N.L., Kaszkin-Bettag M., Carpenter J.E., Gagnier J.J. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol. 2017; 89: 218–35. doi:10.1016/j.jclinepi.2017.04.026.; MacDonald I., Nixon N.A., Khan O.F. Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies. Curr Oncol. 2022; 29(7): 4768–78. doi:10.3390/curroncol29070378.; Liedtke C., Mazouni C., Hess K.R., André F., Tordai A., Mejia J.A., Symmans W.F., Gonzalez-Angulo A.M., Hennessy B., Green M., Cristofanilli M., Hortobagyi G.N., Pusztai L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. J Clin Oncol. 2023; 41(10): 1809–15. doi:10.1200/JCO.22.02572.; Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., Bonnefoi H., Cameron D., Gianni L., Valagussa P., Swain S.M., Prowell T., Loibl S., Wickerham D.L., Bogaerts J., Baselga J., Perou C., Blumenthal G., Blohmer J., Mamounas E.P., Bergh J., Semiglazov V., Justice R., Eidtmann H., Paik S., Piccart M., Sridhara R., Fasching P.A., Slaets L., Tang S., Gerber B., Geyer C.E. Jr, Pazdur R., Ditsch N., Rastogi P., Eiermann W., von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384(9938): 164–72. doi:10.1016/S0140-6736(13)62422-8. Erratum in: Lancet. 2019; 393(10175): 986. doi:10.1016/S0140-6736-(18)32772-7.; Berry D.A., Cirrincione C., Henderson I.C., Citron M.L., Budman D.R., Goldstein L.J., Martino S., Perez E.A., Muss H.B., Norton L., Hudis C., Winer E.P. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006; 295(14): 1658–67. doi:10.1001/jama.295.14.1658. Erratum in: JAMA. 2006; 295(20): 2356.; Zaheed M., Wilcken N., Willson M.L., O’Connell D.L., Goodwin A. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Cochrane Database Syst Rev. 2019; 2(2). doi:10.1002/14651858.CD012873.pub2.; Bines J., Small I.A., Sarmento R., Kestelman F., Silva S., Rodrigues F.R., Faroni L., Gonçalves A., Ebecken E., Maroun P., Millen E., Bonamino M. Does the Sequence of Anthracycline and Taxane Matter? The NeoSAMBA Trial. Oncologist. 2020; 25(9): 758–64. doi:10.1634/theoncologist.2019-0805.; Bacinschi X.E., Anghel R.M., Toma P.I., Safta I., Ilie A., Ilie S.M. Pathologic Response After Weekly Paclitaxel versus Docetaxel in Operable Breast Cancer. Cancer Manag Res. 2020; 12: 1419–26. doi:10.2147/CMAR.S234527.; Korde L.A., Somerfield M.R., Carey L.A., Crews J.R., Denduluri N., Hwang E.S., Khan S.A., Loibl S., Morris E.A., Perez A., Regan M.M., Spears P.A., Sudheendra P.K., Symmans W.F., Yung R.L., Harvey B.E., Hershman D.L. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021; 39(13): 1485–505. doi:10.1200/JCO.20.03399.; Pandy J.G.P., Balolong-Garcia J.C., Cruz-Ordinario M.V.B., Que F.V.F. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer. 2019; 19(1): 1065. doi:10.1186/s12885-019-6253-5.; Ding Y., Ding K., Yang H., He X., Mo W., Ding X. Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients. PLoS One. 2020; 15(5). doi:10.1371/journal.pone.0234058.; Wang X., He Y., Wang T., Xie Y., Li J., Ouyang T., Fan Z. Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer. Support Care Cancer. 2019; 27(8): 3019–25. doi:10.1007/s00520-018-4572-8.; https://www.siboncoj.ru/jour/article/view/3204

Availability: https://www.siboncoj.ru/jour/article/view/3204
https://doi.org/10.21294/1814-4861-2024-23-4-186-193

Assessment of the safety and feasibility of neoadjuvant chemotherapy (2 cycles of FLOT chemotherapy + chemoradiotherapy) followed by surgery in the treatment of locally advanced gastric cancer ; Оценка безопасности и воспроизводимости неоадъювантного (2 цикла химиотерапии по схеме FLOT + химиолучевая терапия) и хирургического этапов лечения пациентов с местнораспространенным раком желудка

Authors: D. Yu. Mironova, V. Yu. Skoropad, I. V. Kolobaev, S. A. Ivanov, A. D. Kaprin, Д. Ю. Миронова, В. Ю. Скоропад, И. В. Колобаев, С. A. Иванов, А. Д. Каприн

Source: Siberian journal of oncology; Том 23, № 1 (2024); 45-52 ; Сибирский онкологический журнал; Том 23, № 1 (2024); 45-52 ; 2312-3168 ; 1814-4861

Subject Terms: послеоперационные осложнения, neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, toxicity, surgical treatment, postoperative complications, неоадъювантная химиотерапия, неоадъювантная химиолучевая терапия, токсичность, хирургическое лечение

File Description: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/2963/1201; Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–49. doi:10.3322/caac.21660.; Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2013. 288 с.; Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., Scarffe J.H., Lofts F.J., Falk S.J., Iveson T.J., Smith D.B., Langley R.E., Verma M., Weeden S., Chua Y.J., MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1): 11–20. doi:10.1056/NEJMoa055531.; Al-Batran S.E. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluoruoracil or capecitabin (ECF/ECX) for resectable gastric or gastroesophageal junction (G.EJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. Abs. ASCO 2017 #4004. J Clin Oncol. NCT01216644.; van Hagen P., Hulshof M.C., van Lanschot J.J., Steyerberg E.W., van Berge Henegouwen M.I., Wijnhoven B.P., Richel D.J., Nieuwenhuijzen G.A., Hospers G.A., Bonenkamp J.J., Cuesta M.A., Blaisse R.J., Busch O.R., ten Kate F.J., Creemers G.J., Punt C.J., Plukker J.T., Verheul H.M., Spillenaar Bilgen E.J., van Dekken H., van der Sangen M.J., Rozema T., Biermann K., Beukema J.C., Piet A.H., van Rij C.M., Reinders J.G., Tilanus H.W., van der Gaast A.; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22): 2074–84. doi:10.1056/NEJMoa1112088.; Leong T., Smithers B.M., Haustermans K., Michael M., Gebski V., Miller D., Zalcberg J., Boussioutas A., Findlay M., O’Connell R.L., Verghis J., Willis D., Kron T., Crain M., Murray W.K., Lordick F., Swallow C., Darling G., Simes J., Wong R. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol. 2017; 24(8): 2252–8. doi:10.1245/s10434-017-5830-6.; Ronellenfitsch U., Schwarzbach M., Hofheinz R., Kienle P., Kieser M., Slanger T.E., Burmeister B., Kelsen D., Niedzwiecki D., Schuhmacher C., Urba S., van de Velde C., Walsh T.N., Ychou M., Jensen K. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer. 2013; 49(15): 3149–58. doi:10.1016/j.ejca.2013.05.029.; Zhu Y., Chen J., Sun X., Lou Y., Fang M., Zhou F., Zhang L., Xin Y. Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: a systematic review and meta-analysis. Front Oncol. 2023; 13. doi:10.3389/fonc.2023.1177557.; Zhang X.T., Zhang Z., Liu L., Xin Y.N., Xuan S.Y. Comparative study of neoadjuvant therapy for locally advanced gastric cancer. Chin J Cancer Prev Treat. 2016; 23(11): 739–43. doi:10.1007/s00432-006-0126-4.; Stahl M., Walz M.K., Riera-Knorrenschild J., Stuschke M., Sandermann A., Bitzer M., Wilke H., Budach W. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. Eur J Cancer. 2017; 81: 183–90. doi:10.1016/j.ejca.2017.04.027.; Al-Batran S.E., Homann N., Pauligk C., Goetze T.O., Meiler J., Kasper S., Kopp H.G., Mayer F., Haag G.M., Luley K., Lindig U., Schmiegel W., Pohl M., Stoehlmacher J., Folprecht G., Probst S., Prasnikar N., Fischbach W., Mahlberg R., Trojan J., Koenigsmann M., Martens U.M., Thuss-Patience P., Egger M., Block A., Heinemann V., Illerhaus G., Moehler M., Schenk M., Kullmann F., Behringer D.M., Heike M., Pink D., Teschendorf C., Löhr C., Bernhard H., Schuch G., Rethwisch V., von Weikersthal L.F., Hartmann J.T., Kneba M., Daum S., Schulmann K., Weniger J., Belle S., Gaiser T., Oduncu F.S., Güntner au M., Hozaeel W., Reichart A., Jäger E., Kraus T., Mönig S., Bechstein W.O., Schuler M., Schmalenberg H., Hofheinz R.D., on behalf of theFLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019; 393(10184): 1948–57. doi:10.1016/S0140-6736(18)32557-1.; https://www.siboncoj.ru/jour/article/view/2963

Availability: https://www.siboncoj.ru/jour/article/view/2963
https://doi.org/10.21294/1814-4861-2024-23-1-45-52

Integrin profile of circulating tumour cells in breast cancer patients ; Интегриновый профиль циркулирующих опухолевых клеток у больных раком молочной железы

Authors: E. S. Grigoryeva, L. A. Tashireva, V. V. Alifanov, M. V. Zavyalova, V. M. Perelmuter, Е. С. Григорьева, Л. А. Таширева, В. В. Алифанов, М. В. Завьялова, В. М. Перельмутер

Contributors: The study was supported by the Russian Science Foundation (grant No. 21-15-00140)., Исследование было поддержано Российским научным фондом (грант № 21-15-00140 «Прогнозирование локализации гематогенных метастазов при раке молочной железы»).

Source: Siberian journal of oncology; Том 23, № 4 (2024); 86-95 ; Сибирский онкологический журнал; Том 23, № 4 (2024); 86-95 ; 2312-3168 ; 1814-4861

Subject Terms: неоадъювантная химиотерапия, circulating tumor cells, integrins, neoadjuvant chemotherapy, циркулирующие опухолевые клетки, интегрины

File Description: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/3195/1254; Su C.Y., Li J.Q., Zhang L.L., Wang H., Wang F.H., Tao Y.W., Wang Y.Q., Guo Q.R., Li J.J., Liu Y., Yan Y.Y., Zhang J.Y. The Biological Functions and Clinical Applications of Integrins in Cancers. Front Pharmacol. 2020; 11. doi:10.3389/fphar.2020.579068.; Cooper J., Giancotti F.G. Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell. 2019; 35(3): 347–67. doi:10.1016/j.ccell.2019.01.007.; Liu F., Wu Q., Dong Z., Liu K. Integrins in cancer: Emerging mechanisms and therapeutic opportunities. Pharmacol Ther. 2023; 247. doi:10.1016/j.pharmthera.2023.108458.; Seguin L., Kato S., Franovic A., Camargo M.F., Lesperance J., Elliott K.C., Yebra M., Mielgo A., Lowy A.M., Husain H., Cascone T., Diao L., Wang J., Wistuba I.I., Heymach J.V., Lippman S.M., Desgrosellier J.S., Anand S., Weis S.M., Cheresh D.A. An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014; 16(5): 457–68. doi:10.1038/ncb2953.; Zahir N., Lakins J.N., Russell A., Ming W., Chatterjee C., Rozenberg G.I., Marinkovich M.P., Weaver V.M. Autocrine laminin-5 ligates a6h4 integrin and activates RAC and NFnB to mediate anchorage-independent survival of mammary tumors. J Cell Biol. 2003; 163(6): 1397–407. doi:10.1083/jcb.200302023.; Sharifi M., Zarrin B., Bahri Najafi M., Hakimian M.R., Hosseini N., Talebi K., Javanmard S.H. Integrin α6 β4 on Circulating Tumor Cells of Metastatic Breast Cancer Patients. Adv Biomed Res. 2021; 10. doi:10.4103/abr.abr_76_21.; Поспелова Р.А. Лейкоконцентрация в клинической практике: диагностическое значение. M., 1973. 88 с.; Kovacheva M., Zepp M., Berger S., Berger M.R. Conditional knock-down of integrin beta-3 reveals its involvement in osteolytic and soft tissue lesions of breast cancer skeletal metastasis. J Cancer Res Clin Oncol. 2021; 147(2): 361–71. doi:10.1007/s00432-020-03428-y.; Parvani J.G., Galliher-Beckley A.J., Schiemann B.J., Schiemann W.P. Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β. Mol Biol Cell. 2013; 24(21): 3449–59. doi:10.1091/mbc.E12-10-0776. Erratum in: Mol Biol Cell. 2014; 25(4): 548.; Giampieri S., Manning C., Hooper S., Jones L., Hill C.S., Sahai E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009; 11(11): 1287–96. doi:10.1038/ncb1973.; Liu L., Yang L., Yan W., Zhai J., Pizzo D.P., Chu P., Chin A.R., Shen M., Dong C., Ruan X., Ren X., Somlo G., Wang S.E. Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. Clin Cancer Res. 2018; 24(10): 2370–82. doi:10.1158/1078-0432.CCR-17-2545.; https://www.siboncoj.ru/jour/article/view/3195

Availability: https://www.siboncoj.ru/jour/article/view/3195
https://doi.org/10.21294/1814-4861-2024-23-4-86-95

Efficacy of total neoadjuvant chemotherapy in the FLOT regimen in patients with locally advanced gastric and gastroesophageal junction: results of a phase II study ; Эффективность полной неоадъювантной химиотерапии в режиме FLOT у пациентов с местно-распространенным раком желудка и кардиоэзофагеального перехода: результаты исследования II фазы

Authors: A. Yu. Anokhin, P. V. Kononets, D. Yu. Kanner, D. L. Stroyakovsky, A. O. Shveykin, A. E. Kalinin, V. Yu. Kirsanov, A. S. Tyulandina, А. Ю. Анохин, П. В. Кононец, Д. Ю. Каннер, Д. Л. Строяковский, А. О. Швейкин, А. Е. Калинин, В. Ю. Кирсанов, А. С. Тюляндина

Source: Surgery and Oncology; Том 14, № 1 (2024); 62-71 ; Хирургия и онкология; Том 14, № 1 (2024); 62-71 ; 2949-5857

Subject Terms: гастрэктомия, gastroesophageal junction cancer, locally advanced gastric cancer, perioperative chemotherapy, total neoadjuvant chemotherapy, pathomorphological regression, gastrectomy, рак кардиоэзофагеального перехода, местно-распространенный рак желудка, периоперационная химиотерапия, полная неоадъювантная химиотерапия, патоморфологический регресс опухоли

File Description: application/pdf

Relation: https://www.onco-surgery.info/jour/article/view/692/457; Давыдов М.И., Туркин И.Н., Давыдов М.М. Энциклопедия хирургии рака желудка. М.: Эксмо, 2011.; Шаназаров Н.А., Синяков А.Г., Райков Н.С. и др. Различные объемы лимфодиссекции в хирургическом лечении рака желудка. Тюменский медицинский журнал 2010;2:89–92.; Дмитриев Е.Г., Михайлова Н.В. Хирургическое лечение рака желудка: современное состояние и перспективы. Поволжский онкологический вестник 2010;4:74–81.; Catalano V., Labianca R., Beretta G. et al. Gastric cancer. Crit Rev Oncol Hematol 2009;71:127–64. DOI:10.1016/j.critrevonc.2009.01.004; Бесова Н.С., Калинин А.Е., Неред С.Н. и др. Ассоциация онкологов России. Клинические рекомендации по лечению рака желудка. 2020 год. https://oncology-association.ru/wp-content/uploads/2020/09/rak_zheludka.pdf; Cunningham D., Allum W., Stenning S. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20. DOI:10.1056/NEJMoa055531; Al-Batran S.E., Homann N., Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastrooesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393(10184):1948–57. DOI:10.1016/S0140-6736(18)32557-1; Бесова Н.С., Болотина Л.В., Гамаюнов С.В. и др. Практические рекомендации по лекарственному лечению рака желудка. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли 2023;13(3):405–24. DOI:10.18027/2224-5057-2023-13-3s2-1-405-424; NCCN Clinical Practice Guidelines in oncology. Gastric cancer. – National Comprehensive Cancer Network, version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf; Ychou M., Boige V., Pignon J. et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. JCO 2011;29(13):1715–21. DOI:10.1200/JCO.2010.33.0597; Mandard A., Dalibard F., Mandard J. et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73(11):2680–6. DOI:10.1002/1097-0142(19940601)73:113.0.co;2-c; Ma J., Jianhui L., Meirui Q. et al. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N). Diagn Pathol 2018;13(1):91–101. DOI:10.1186/s13000-018-0766-0; Giommoni E., Lavacchi D., Tirino G. et al. Results of the observational prospective RealFLOT study. BMC Cancer 2021;21:1086–96. DOI:10.1186/s12885-021-08768-7; Muro K., Chung H.C., Shankaran V. et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016;17:717–26. DOI:10.1016/S1470-2045(16)00175-3; Smyth E., Wotherspoon A., Peckitt C. et al. Mismatch repair deficiency, microsatellite instability, and survival an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial. JAMA Oncol 2017;3(9):1197–203. DOI:10.1001/jamaoncol.2016.6762; Сунь Х., Неред С.Н., Трякин А.А. и др. Результаты комбинированного лечения резектабельного рака желудка в зависимости от статуса микросателлитной нестабильности. Тазовая хирургия и онкология 2023;13(2):17–26. DOI:10.17650/2686-9594-2023-13-2-17-26

Availability: https://www.onco-surgery.info/jour/article/view/692
https://doi.org/10.17650/2949-5857-2024-14-1-62-71

The influence of modern computer and magnetic resonance imaging technologies on the preoperative staging of pancreatic cancer ; Влияние современных технологий компьютерной и магнитно-резонансной томографии на дооперационное стадирование рака поджелудочной железы

Authors: Alexandra V. Zharikova, Evgeny V. Kondratyev, Valeriya S. Tikhonova, Ivan S. Gruzdev, Mikhail V. Rostovtsev, Pavel V. Markov, Vladimir Yu. Struchkov, Grigory G. Karmazanovsky, А. В. Жарикова, Е. В. Кондратьев, В. С. Тихонова, И. С. Груздев, М. В. Ростовцев, П. В. Марков, В. Ю. Стручков, Г. Г. Кармазановский

Source: Medical Visualization; Том 28, № 2 (2024); 118-133 ; Медицинская визуализация; Том 28, № 2 (2024); 118-133 ; 2408-9516 ; 1607-0763

Subject Terms: МРТ, вовлечение сосудов, местнораспространенная опухоль, неоадъювантная химиотерапия, КТ

File Description: application/pdf

Relation: https://medvis.vidar.ru/jour/article/view/1452/873; ACS Journals, Cancer statistics 2020, http://doi.org/10.3322/caac.21590; Злокачественные новообразования в России в 2020 году (заболеваемость и смертность) / Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. 2021.; Park W., Chawla A., O’Reilly E.M. Pancreatic Cancer: A Review. JAMA. 2021; 326 (9): 851–862. https://doi.org/10.1001/jama.2021.13027; Buchs N.C., Chilcott M., Poletti P.-A. et al. Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management. Wld J. Gastroenterol. 2010; 16 (7): 818–831. https://doi.org/10.3748/wjg.v16.i7.818; Al-Hawary M.M., Francis I.R., Chari S.T. et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology. 2014; 270 (1): 248–260. https://doi.org/10.1148/radiol.13131184; Клинические рекомендации Министерства здравоохранения РФ “Рак поджелудочной железы, 2021 год” https://cr.minzdrav.gov.ru/schema/355_4; Gugenheim J., Crovetto A., Petrucciani N. Neoadjuvant therapy for pancreatic cancer. Updates Surg. 2022; 74 (1): 35–42. https://doi.org/10.1007/s13304-021-01186-1; Seufferlein T., Uhl W., Kornmann M. et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX) – a randomized phase II trial of the AIO pancreatic cancer group. Ann. Oncol. 2023; 34 (1): 91–100. https://doi.org/10.1016/j.annonc.2022.09.161; Ghaneh P., Palmer D., Cicconi S. et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol. Hepatol. 2023; 8 (2): 157–168. https://doi.org/10.1016/S2468-1253(22)00348-X; NCCN Guidelines for Pancreatic Adenocarcinoma. V.1., 2023.; Lee E.S., Lee J.M. Imaging diagnosis of pancreatic cancer: a state-of-the-art review. Wld J. Gastroenterol. 2014; 20 (24): 7864–7877. https://doi.org/10.3748/wjg.v20.i24.7864; Kim Y.K., Lee M.W., Lee W.J. et al. Diagnostic Accuracy and Sensitivity of Diffusion-Weighted and of Gadoxetic Acid-Enhanced 3-T MR Imaging Alone or in Combination in the Detection of Small Liver Metastasis (≤1.5 cm in Diameter). Invest. Radiol. 2012; 47 (3): 159–66. https://doi.org/10.1097/rli.0b013e31823a1495; Кармазановский Г.Г. Опухоли поджелудочной железы солидной структуры: стадирование и резектабельность, критерии оценки прогрессирования опухолевого процесса после хирургического лечения (лекция, часть 2). Медицинская визуализация. 2016; 5: 43–49.; Шима В., Кауэлблингер К. Аденокарцинома поджелудочной железы: выявление, определение стадии и дифференциальная диагностика. Медицинская визуализация. 2015; 5: 52–72.; Ветшева Н.Н. Дооперационная диагностика солидных опухолей поджелудочной железы: обзор литературы. Медицинская визуализация. 2016; 5: 50–58.; Kamisawa T., Takuma K., Anjiki H. et al. Differentiation of autoimmune pancreatitis from pancreatic cancer by diffusion-weighted MRI. Am. J. Gastroenterol. 2010; 105 (8): 1870–1875. https://doi.org/10.1038/ajg.2010.87; Uzunoglu F.G., Welte M.-N., Gavazzi F. et al. Evaluation of the MDACC clinical classification system for pancreatic cancer patients in an European multicenter cohort. Eur. J. Surg. Oncol. 2019; 45 (5): 793–799. https://doi.org/10.1016/j.ejso.2018.12.012; Sohal D.P.S., Kennedy E.B., Cinar P. et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J. Clin. Oncol. 2020; 38 (27): 3217–3230. https://doi.org/10.1200/JCO.20.01364; Isaji S., Mizuno S., Windsor J.A. et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018; 18 (1): 2–11. https://doi.org/10.1016/j.pan.2017.11.011; Покатаев И.А., Гладков О.А., Загайнов В.Е., Кудашкин Н.Е., Кучин Д.М., Лядов В.К. и др. Практические рекомендации по лекарственному лечению рака поджелудочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2022; 12: 530–544. https://doi.org/10.18027/2224-5057-2022-12-3s2-530-544; Fujita T., Nakagohri T., Gotohda N. et al. Evaluation of the prognostic factors and significance of lymph node status in invasive ductal carcinoma of the body or tail of the pancreas. Pancreas. 2010; 39 (1): e48–54. https://doi.org/10.1097/MPA.0b013e3181bd5cfa; Kanda M., Fujii T., Nagai S. et al. Pattern of lymph node metastasis spread in pancreatic cancer. Pancreas. 2011; 40: 951–955. https://doi.org/10.1097/MPA.0b013e3182148342; Sergeant G., Melloul E., Lesurtel M. et al. Extended lymphadenectomy in patients with pancreatic cancer is debatable. Wld J. Surg. 2013; 37 (8): 1782–1788. https://doi.org/10.1007/s00268-013-2064-z; Zacharias T., Jaeck D., Oussoultzoglou E. et al. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J. Gastrointest. Surg. 2007; 11: 350–356. https://doi.org/10.1007/s11605-007-0113-3; Henne-Bruns D., Vogel I., Lüttges J. et al. Surgery for ductal adenocarcinoma of the pancreatic head: staging, complications, and survival after regional versus extended lymphadenectomy. Wld J. Surg. 2000; 24 (5): 595–601; discussion 601–602. https://doi.org/10.1007/s002689910089; Murakami Y., Uemura K., Sudo T. et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann. Surg. Oncol. 2011; 18 (3): 651–658. https://doi.org/10.1245/s10434-010-1325-4; Henne-Bruns D., Vogel I., Lüttges J. et al. Ductal adenocarcinoma of the pancreas head: survival after regional versus extended lymphadenectomy. Hepatogastroenterology. 1998; 45 (21): 855–866. PMID: 9684147; Masui T., Kubota T., Aoki K. et al. Long-term survival after resection of pancreatic ductal adenocarcinoma with para-aortic lymph node metastasis: case report. Wld J. Surg. Oncol. 2013; 11 (1): 195. https://doi.org/10.1186/1477-7819-11-195; Kaťuchová J., Bober J., Kaťuch V., Radoňak J. Significance of lymph node micrometastasis in pancreatic cancer patients. Eur. Surg. Res. 2012; 48 (1): 10–15. https://doi.org/10.1159/000334171; Ishikawa O., Ohhigashi H., Sasaki Y. et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann. Surg. 1988; 208 (2): 215–220. https://doi.org/10.1097/00000658-198808000-00014; Nimura Y., Nagino M., Takao S. et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: Long-term results of a japanese multicenter randomized controlled trial. J. Hepatobiliary. Pancreat. Sci. 2012; 19: 230–241. https://doi.org/10.1007/s00534-011-0466-6; Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14: 101–112. https://doi.org/10.1007/s10120-011-0041-5; Базин И.С., Покатаев И.А., Попова А.С., Базина И.В., Чихарева Я.Е. Место химиотерапии в лечении локализованного рака поджелудочной железы. Злокачественные опухоли. 2016; 4 (спецвыпуск 1): 20–25. https://doi.org/10.18027/2224-5057-2016-4s1-20-25; Lambert A., Schwarz L., Ducreux M., Conroy T. Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. Cancers (Basel). 2021; 13 (18): 4724. https://doi.org/10.3390/cancers13184724; Springfeld C., Ferrone C.R., Katz M.H.G. et al. Neoadjuvant therapy for pancreatic cancer. Nat. Rev. Clin. Oncol. 2023; 20 (5): 318–337. https://doi.org/10.1038/s41571-023-00746-1; Katz M.H., Fleming J.B., Bhosale P. et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012; 118 (23): 5749–5756. https://doi.org/10.1002/cncr.27636; Ferrone C.R., Marchegiani G., Hong T.S. et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann. Surg. 2015; 261: 12–17. https://doi.org/10.1097/SLA.0000000000000867; Zins M., Matos C., Cassinotto C. Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. Radiology. 2018; 287 (2): 374–390. https://doi.org/10.1148/radiol.2018171670; Chen X., Oshima K., Schott D. et al. Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: An exploratory study. PLoS One. 2017; 12 (6): e0178961. https://doi.org/10.1371/journal.pone.0178961; Navez J., Bouchart C., Lorenzo D. et al. What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact? Ann. Surg. Oncol. 2021; 28 (11): 6211–6222. https://doi.org/10.1245/s10434-020-09568-2.; Barreto S.G., Loveday B., Windsor J.A., Pandanaboyana S. Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. ANZ J. Surg. 2019; 89 (5): 481–487. https://doi.org/10.1111/ans.14764; Yang R., Lu M., Qian X. et al. Diagnostic accuracy of EUS and CT of vascular invasion in pancreatic cancer: a systematic review. J. Cancer. Res. Clin. Oncol. 2014; 140 (12): 2077–2086. https://doi.org/10.1007/s00432-014-1728-x; Zimmermann C., Distler M., Jentsch C. et al. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11). Strahlenther. Onkol. 2021; 197 (1): 19–26. https://doi.org/10.1007/s00066-020-01654-4; Nishiofuku H., Tanaka T., Marugami N. et al. Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer. Eur. Radiol. 2016; 26 (6): 1835–1842. https://doi.org/10.1007/s00330-015-3999-2; Cozzi L., Comito T., Fogliata A. et al. Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. PLoS One. 2019; 14 (1): e0210758. https://doi.org/10.1371/journal.pone.0210758; Nasief H., Hall W., Zheng C. et al. Improving Treatment Response Prediction for Chemoradiation Therapy of Pancreatic Cancer Using a Combination of Delta-Radiomics and the Clinical Biomarker CA19-9. Front. Oncol. 2020; 9: 1464. https://doi.org/10.3389/fonc.2019.01464; Ciaravino V., Cardobi N., De Robertis R. et al. CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy. Anticancer Res. 2018; 38 (8): 4889–4895. https://doi.org/10.21873/anticanres.12803; Chen F., Zhou Y., Qi X. et al. CT texture analysis for the presurgical prediction of superior mesenteric-portal vein invasion in pancreatic ductal adenocarcinoma: comparison with CT imaging features. Clin. Radiol. 2021; 76 (5): 358–366. https://doi.org/10.1016/j.crad.2021.01.003; Rigiroli F., Hoye J., Lerebours R. et al. CT Radiomic Features of Superior Mesenteric Artery Involvement in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Radiology. 2021; 301 (3): 610–622. https://doi.org/10.1148/radiol.2021210699; Bian Y., Jiang H., Ma C. et al. Performance of CT-based radiomics in diagnosis of superior mesenteric vein resection margin in patients with pancreatic head cancer. Abdom. Radiol. (NY). 2020; 45 (3): 759–773. https://doi.org/10.1007/s00261-019-02401-9; https://medvis.vidar.ru/jour/article/view/1452

Availability: https://medvis.vidar.ru/jour/article/view/1452
https://doi.org/10.24835/1607-0763-1452

Changes in clinical guidelines for the treatment of colorectal cancer in 2024 ; Изменения в клинических рекомендациях по лечению колоректального рака в 2024 году

Authors: S. S. Gordeev, M. Yu. Fedyanin, M. V. Chernykh, Ye. G. Rubakov, A. M. Karachun, A. A. Nevolskikh, A. A. Tryakin, Z. Z. Mamedli, С. С. Гордеев, М. Ю. Федянин, М. В. Черных, Е. Г. Рыбаков, А. М. Карачун, А. А. Невольских, А. А. Трякин, З. З. Мамедли

Source: Surgery and Oncology; Том 14, № 1 (2024); 21-31 ; Хирургия и онкология; Том 14, № 1 (2024); 21-31 ; 2949-5857

Subject Terms: тотальная неоадъювантная терапия, colon cancer, colorectal cancer, clinical guidelines, neoadjuvant chemotherapy, total neoadjuvant therapy, рак ободочной кишки, колоректальный рак, клинические рекомендации, неоадъювантная химиотерапия

File Description: application/pdf

Relation: https://www.onco-surgery.info/jour/article/view/687/451; Sakamoto T., Shimura M., Kitano S. et al. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007;243(1):132–9. DOI:10.1148/radiol.2431051825; Engstrom P.F., Arnoletti J.P., Benson A.B. 3rd et al. Rectal cancer. J Natl Compr Canc Netw 2009:7(8):838–81. DOI:10.6004/jnccn.2009.0057; De Caluwé L., Van Nieuwenhove Y., Ceelen W.P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2013(2):CD006041. DOI:10.1002/14651858.CD006041.pub3; Bahadoer R.R., Dijkstra E.A., van Etten B. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22(1):29–42. DOI:10.1016/S1470-2045(20)30555-6; Dijkstra E.A., Nilsson P.J., Hospers G.A.P. et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery–a five-year follow-up of the RAPIDO trial. Ann Surg 2023;278(4):e766–72. DOI:10.1097/SLA.0000000000005799; Song J.H., Jeong J.U., Lee J.H. et al. Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for stage II–III resectable rectal cancer: a meta-analysis of randomized controlled trials. Radiat Oncol J 2017;35(3): 198–207. DOI:10.3857/roj.2017.00059; Battersby N.J., How P., Moran B. et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg 2016;263(4):751–60. DOI:10.1097/SLA.0000000000001193; Marinello F.G., Frasson M., Baguena G. et al. Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary. Dis Colon Rectum 2015;58(6):556–65. DOI:10.1097/DCR.0000000000000349; Rosenberg R., Maak M., Schuster T. et al. Does a rectal cancer of the upper third behave more like a colon or a rectal cancer? Dis Colon Rectum 2010;53(5):761–70. DOI:10.1007/DCR.0b013e3181cdb25a; Folkesson J., Birgisson H., Pahlman L. et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005;23(24):5644–50. DOI:10.1200/JCO.2005.08.144; Sebag-Montefiore D., Stephens R.J., Steele R. et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373(9666):811–20. DOI:10.1016/S0140-6736(09)60484-0; Van Gijn W., Marijnen C.A., Nagtegaal I.D. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12(6):575–82. DOI:10.1016/S1470-2045(11)70097-3; Morton D., Seymour M., Magill L. et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol 2023;41(8):1541. DOI:10.1200/JCO.22.00046; Hu H., Huang M., Li Y. et al. Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial. J Clin Oncol 2022;40(16_suppl). DOI:10.1200/JCO.2022.40.16_suppl.3500; Jensen L.H., Kjaer M.L., Holländer N.H., Larsen F.O. Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. J Clin Oncol 2023;41(17_suppl):LBA3503. DOI:10.1200/JCO.2023.41.17_suppl.LBA3503; Karoui M., Rullier A., Piessen G. et al. Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22). Ann Surg 2020;271(4):637–45. DOI:10.1097/SLA.0000000000003454; Ngan S.Y., Burmeister B., Fisher R.J. et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012;30(31):3827–33. DOI:10.1200/JCO.2012.42.9597; Cisel B., Pietrzak L., Michalski W. et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol 2019;30(8):1298–303. DOI:10.1093/annonc/mdz186; Dijkstra E.A., Hospers G.A.P., Kranenbarg E.M. et al. Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial. Radiother Oncol 2022;171:69–76. DOI:10.1016/j.radonc.2022.04.013; Birgisson H., Påhlman L., Gunnarsson U., Glimelius B. Late adverse effects of radiation therapy for rectal cancer – a systematic overview. Acta Oncol 2007;46(4):504–16. DOI:10.1080/02841860701348670; Grothey A., Sobrero A.F., Shields A.F. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378(13):1177–88. DOI:10.1056/NEJMoa1713709; Schrag D. PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC)(Alliance N1048). American Society of Clinical Oncology 2023.; Mei W.-J., Wang X.Z., Li Y.F. et al. Neoadjuvant chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): initial results of a phase III trial. Ann Surg 2023;277(4):557–64. DOI:10.1097/SLA.0000000000005780; Hazen S.-M.J., Sluckin T.C., Intven M.P.W. et al. Abandonment of Routine Radiotherapy for Nonlocally Advanced Rectal Cancer and Oncological Outcomes. JAMA Oncol 2024;10(2):202–11. DOI:10.1001/jamaoncol.2023.5444; Sychev S., Ponomarenko A., Chernyshov S. et al. Total neoadjuvant therapy in rectal cancer: a network meta-analysis of randomized trials. Ann Coloproctol 2023;39(4):289–300. DOI:10.3393/ac.2022.00920.0131; Verheij F.S., Omer D.M., Williams H. et al. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol 2023:42(5):500–6. DOI:10.1200/JCO.23.01208; Liao C.-K., Kuo Y.T., Lin Y.C. et al. Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer: a systematic review and meta-analysis. Curr Oncol 2022;29(5):3708–27. DOI:10.3390/curroncol29050297; Verheij F.S., Omer D.M.R., Williams H. et al. Sustained organ preservation in patients with rectal cancer treated with total neoadjuvant therapy: Long-term results of the OPRA trial. J Clin Oncol 2023;41(16_suppl). DOI:10.1200/JCO.2023.41.16_suppl.352; Romesser P.B., Park B.K., Nemirovsky D. et al. Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy. J Clin Oncol 2023;41(4_suppl). DOI:10.1200/JCO.2023.41.4_suppl.10; Van der Valk M.J., Hilling D.E., Bastiaannet E. et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 2018;391(10139):2537–45. DOI:10.1016/S0140-6736(18)31078-X; Ellis C.T., Cole A.L., Sanoff H.K. et al. Evaluating surveillance patterns after Chemoradiation-only compared with conventional Management for Older Patients with rectal cancer. J Am Coll Surg 2019;228(5):782–91. DOI:10.1016/j.jamcollsurg.2019.01.010; Giordano P., Efron J., Vernava A.M. 3rd et al. Strategies of followup for colorectal cancer: a survey of the American Society of Colon and Rectal Surgeons. Tech Coloproctol 2006;10(3):199–207. DOI:10.1007/s10151-006-0280-3; Федянин М., Гладков О., Гордеев С. и др. Рак ободочной кишки, ректосигмоидного соединения и прямой кишки. Злокачественные опухоли 2023;13(3s2-1):425–82. DOI:10.18027/2224-5057-2023-13-3s2-1-425-482; Федянин М., Трякин А.А., Буланов А.А. и др. К вопросу о числе лимфатических узлов, необходимых к изучению при раке толстой кишки II стадии. Тазовая хирургия и онкология 2019;9(1):42–50. DOI:10.17650/2220-3478-2019-9-1-42-50; Jeon J., Shen L., Kim Y. et al. The number of lymph nodes examined as a poor prognosis factor in stage II and stage III colon cancer patients undergoing curative surgery. J Clin Oncol 2023;41(16_suppl). DOI:10.1200/JCO.2023.41.16_suppl.3612; Ahmed F., Selfridge J., Kakishet H. et al. SO-19 The outcome of resected stage II colon cancer patients with deficient mismatch repair T4 tumors: A National Cancer Database analysis. Ann Oncol 2023;34(1_suppl):S170. DOI:10.1016/j.annonc.2023.04.491; Fleming P., Chen Ch., Moore D.F. et al. High-risk MSI-H stage II colon cancer: Treatment patterns and outcomes. J Clin Oncol 2022;40(16_suppl). DOI:10.1200/JCO.2022.40.16_suppl.e15588; Oki E., Kotani D., Nakamura Y. et al. Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan. J Clin Oncol 2023;41(16_suppl). DOI:10.1200/JCO.2023.41.16_suppl.3521; Tie J., Cohen J.D., Lahouel K. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022;386(24):2261–72. DOI:10.1056/NEJMoa2200075; Cohen S.A., Kasi P.M., Aushev V.N., Hanna D. Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I–III colorectal cancer. J Clin Oncol 2023;41(4_suppl):5. DOI:10.1200/JCO.2023.41.4_suppl.5; Karoui M., Gallois C., Piessen G. et al. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years’ follow-up results of the PRODIGE 22 phase II randomized multicentre trial. Colorectal Dis 2021;23(6):1357–69. DOI:10.1111/codi.15585

Availability: https://www.onco-surgery.info/jour/article/view/687
https://doi.org/10.17650/2949-5857-2024-14-1-21-31

The Utility of Radiation Imaging during the Treatment of Head and Neck Tumors with Neoadjuvant Chemotherapy: Оценка информативности лучевых методов исследования при лечении опухолей головы и шеи с использованием неоадъювантной химиотерапии

Authors: Volodina, V.D., Reshetov, I.V., Serova, N.S., Romanko, Yu.S.

Source: Head and neck. Russian Journal. 11

Subject Terms: squamous cell carcinoma, магнитно-резонансная томография, радиоизотопная диагностика, компьютерная томография, ultrasound, плоскоклеточный рак, computed tomography, лучевая диагностика, 3. Good health, head and neck tumors, опухоли головы и шеи, diagnostics, magnetic resonance imaging, radiation diagnostics, ультразвуковое исследование, neoadjuvant chemotherapy, неоадъювантная химиотерапия

ERCC1 as a prognostic marker of the clinical effect of neoadjuvant chemotherapy in patients with locally advanced cervical cancer

Source: Евразийский онкологический журнал. :169-179

Subject Terms: 03 medical and health sciences, 0302 clinical medicine, platinum-based drugs, cervical cancer, препараты платины, рак шейки матки, ERCC1, 3. Good health, неоадъювантная химиотерапия, neoadjuvant chemotherapy

Long-term results of combined treatment of triple-negative breast cancer

Authors: Vinnyk, Yuriy, Vlasenko, Vadim, Baranova, Anna

Source: ScienceRise: Medical Science; № 3 (36) (2020); 33-37

Subject Terms: тричі-негативний рак молочної залози, радикальна операція, комбіноване лікування, віддалений результат, неоад'ювантна хіміотерапія, УДК 618.19-006-089-06, triple negative breast cancer, radical surgery, combination treatment, long-term outcome, neoadjuvant chemotherapy, трижды-негативный рак молочной железы, радикальная операция, комбинированное лечение, отдаленный результат, неоадъювантная химиотерапия, 3. Good health

File Description: application/pdf

Access URL: http://journals.uran.ua/sr_med/article/download/203371/204273
http://journals.uran.ua/sr_med/article/download/203371/204273
https://www.neliti.com/publications/313668/long-term-results-of-combined-treatment-of-triple-negative-breast-cancer
http://journals.uran.ua/sr_med/article/view/203371
http://journals.uran.ua/sr_med/article/view/203371

Current approaches to systemic treatment of BRCA-associated triple-negative breast cancer ; Современные подходы к системному лечению BRCA-ассоциированного трижды негативного рака молочной железы

Authors: Enaldieva D.A., Krivorotko P.V., Imyanitov E.N., Zhiltsova E.K., Donskikh R.V., Shaikhelislamova L.F., Gigolaeva L.P., Semiglazov V.F.

Contributors: This study was supported by the Russian Science Foundation (grand No. 22-15-0266)., Работа выполнена при поддержке Российского научного фонда (гранд № 22-15-0266).

Source: Advances in Molecular Oncology; Vol 10, No 3 (2023); 8-14 ; Успехи молекулярной онкологии; Vol 10, No 3 (2023); 8-14 ; 2413-3787 ; 2313-805X

Subject Terms: BRCA1/2 mutations, neoadjuvant chemotherapy, pathological complete response, triple-negative breast cancer, metastatic breast cance, мутации BRCA1/2, неоадъювантная химиотерапия, патологический полный ответ, трижды негативный рак молочной железы, метастатический рак молочной железы

File Description: application/pdf

Relation: https://umo.abvpress.ru/jour/article/view/564/308; https://umo.abvpress.ru/jour/article/view/564

Availability: https://umo.abvpress.ru/jour/article/view/564
https://doi.org/10.17650/2313-805X-2023-10-3-8-14

Total neoadjuvant chemotherapy according to the FOLFIRINOX regimen for locally advanced adenocarcinoma of the stomach and cardioesophageal junction: interim results ; Тотальная неоадъювантная химиотерапия по схеме FOLFIRINOX при местнораспространенной аденокарциноме желудка и кардиоэзофагеального перехода: промежуточные результаты

Authors: M. V. Sedova, M. A. Batov, A. A. Kolomeytseva, V. M. Khomyakov, N. N. Volchenko, A. A. Fedenko, М. В. Седова, М. А. Батов, А. А. Коломейцева, В. М. Хомяков, Н. Н. Волченко, А. А. Феденко

Source: Research and Practical Medicine Journal; Том 10, № 3 (2023); 8-20 ; Research'n Practical Medicine Journal; Том 10, № 3 (2023); 8-20 ; 2410-1893 ; 10.17709/10.17709/2410-1893-2023-10-3

Subject Terms: степень патоморфологической регрессии, neoadjuvant chemotherapy, FOLFIRINOX, FLOT, gastric cancer, gastroesophageal junction cancer, tumor regression grade, неоадъювантная химиотерапия, рак желудка, рак кардиоэзофагеального перехода

File Description: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/932/579; Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016 Nov 26;388(10060):2654–2664. https://doi.org/10.1016/s0140-6736(16)30354-3; Августинович А. В., Афанасьев С. Г., Добродеев А. Ю., Волков М. Ю., Костромицкий Д. Н., Спирина Л. В., Черемисина О. В. Непосредственная эффективность и токсичность тотальной неоадъювантной химиотерапии резектабельного рака желудка. Сибирский онкологический журнал. 2022;21(1):114–119. https://doi.org/10.21294/1814-4861-2022-21-1-11-19; Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al., MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11–20. https://doi.org/10.1056/nejmoa055531; Агабабян Т. А., Силантьева Н. К., Скоропад В. Ю., Иванов С. А., Каприн А. Д., Комин Ю. А., и др. Возможности и ограничения КТ-оценки непосредственного эффекта неоадъювантной химиолучевой терапии рака желудка. Research and Practical Medicine Journal (Исследования и практика в медицине). 2019;6(4):92–101. https://doi.org/10.17709/2409-2231-2019-6-4-9; Маркович В. А., Тузиков С. А., Родионов Е. О., Попова Н. О., Цыганов М. М., Миллер С. В., и др. Комбинированное лечение больных раком желудка IV стадии с канцероматозом брюшины. Сибирский онкологический журнал. 2023;22(1):24–34. https://doi.org/10.21294/1814-4861-2023-22-1-24-34; Бобрышев А. А., Давыдов М. М., Нариманов М. Н., Поликарпова С. Б., Кирсанов В. Ю., Блиндарь В. Н. Роль адъювантной химиотерапии в лечении местнораспространенного рака желудка. Сибирский онкологический журнал. 2021;20(1):133– 140. https://doi.org/10.21294/1814-4861-2021-20-1-133-140; Homann N, Pauligk C, Luley K, Werner Kraus T, Bruch HP, et al. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer. 2012 Apr 1;130(7):1706–1713. https://doi.org/10.1002/ijc.26180; Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al.; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer aſter D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012 Jan 28;379(9813):315–321. https://doi.org/10.1016/s0140-6736(11)61873-4; Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011 May 1;29(13):1715–1721. https://doi.org/10.1200/jco.2010.33.0597; Tokunaga M, Sato Y, Nakagawa M, Aburatani T, Matsuyama T, Nakajima Y, Kinugasa Y. Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. Surg Today. 2020 Jan;50(1):30–37. https://doi.org/10.1007/s00595-019-01896-5 Erratum in: Surg Today. 2020 Apr;50(4):424.; Machairas N, Charalampoudis P, Molmenti EP, Kykalos S, Tsaparas P, Stamopoulos P, Sotiropoulos GC. The value of staging laparoscopy in gastric cancer. Ann Gastroenterol. 2017;30(3):287–294. https://doi.org/10.20524/aog.2017.0133; Franz JL, Cruz AB Jr. The treatment of gastric cancer with combined surgical resection and chemotherapy. J Surg Oncol. 1977;9(2):131–137. https://doi.org/10.1002/jso.2930090206; Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression aſter neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016 Dec;17(12):1697–1708. https://doi.org/10.1016/s1470-2045(16)30531-9; Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al.; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948–1957. https://doi.org/10.1016/s0140-6736(18)32557-1; Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, et al. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Int J Cancer. 2015 Aug 1;137(3):678–685. https://doi.org/10.1002/ijc.29403; Obarevich E, Besova N, Trusilova E, Gorbunova V. Irinotecan, oxaliplatin, 5-fluorouracil/leucovorin (FOLFIRINOX) as first-line therapy in advanced HER2-negative gastric or gastroesophageal adenocarcinoma (G/GEA). Annals of Oncology. 2018;29(Suppl_8). https://doi.org/10.1093/annonc/mdy282.059; Park H, Jin RU, Wang-Gillam A, Suresh R, Rigden C, Amin M, et al. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 Aug 1;6(8):1231–1240. https://doi.org/10.1001/jamaoncol.2020.2020; Seshadri RA, Jayanand SB, Ranganathan R. Prognostic factors in patients with node-negative gastric cancer: an Indian experience. World J Surg Oncol. 2011 May 10;9:48. https://doi.org/10.1186/1477-7819-9-48; Itaimi A, Baraket O, Triki W, Ayed K, Bouchoucha S. Prognostic factors affecting survival and recurrence in gastric carcinoma. Cancer Rep Rev. 2018;2(6):1-4. https://doi.org/10.15761/crr.1000171; Park JM, Ryu WS, Kim JH, Park SS, Kim SJ, Kim CS, Mok YJ. Prognostic factors for advanced gastric cancer: stage-stratified analysis of patients who underwent curative resection. Cancer Res Treat. 2006 Feb;38(1):13–18. https://doi.org/10.4143/crt.2006.38.1.13; Lee JH, Kim MG, Jung MS, Kwon SJ. Prognostic significance of lymphovascular invasion in node-negative gastric cancer. World J Surg. 2015 Mar;39(3):732–739. https://doi.org/10.1007/s00268-014-2846-y; Deng J, You Q, Gao Y, Yu Q, Zhao P, Zheng Y, Fang W, Xu N, Teng L. Prognostic value of perineural invasion in gastric cancer: a systematic review and meta-analysis. PLoS One. 2014 Feb 21;9(2):e88907. https://doi.org/10.1371/journal.pone.0088907; https://www.rpmj.ru/rpmj/article/view/932

Availability: https://www.rpmj.ru/rpmj/article/view/932
https://doi.org/10.17709//2410-1893-2023-10-3-1

The results of treatment for resectable gastric cancer with microsatellite instability ; Результаты комбинированного лечения резектабельного рака желудка в зависимости от статуса микросателлитной нестабильности

Authors: H. Sun, S. N. Nered, A. A. Tryakin, E. V. Artamonova, A. E. Kalinin, V. E. Bugaev, A. M. Stroganova, N. S. Besova, P. P. Arkhiri, V. I. Marshall, R. Sh. Abdulaeva, I. S. Stilidi, Х. Сунь, С. Н. Неред, А. А. Трякин, Е. В. Артамонова, А. Е. Калинин, В. Е. Бугаев, А. М. Строганова, Н. С. Бесова, П. П. Архири, В. И. Маршалл, Р. Ш. Абдулаева, И. С. Стилиди

Contributors: The study was performed without external funding, Исследование проведено без спонсорской поддержки

Source: Surgery and Oncology; Том 13, № 2 (2023); 17-26 ; Хирургия и онкология; Том 13, № 2 (2023); 17-26 ; 2949-5857

Subject Terms: адъювантная химиотерапия, gastric cancer, chemotherapy, neoadjuvant chemotherapy, adjuvant chemotherapy, рак желудка, химиотерапия, неоадъювантная химиотерапия

File Description: application/pdf

Relation: https://www.onco-surgery.info/jour/article/view/602/419; Cunningham D., Allum W.H., Stenning S.P. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355(1):11–20. PMID: 16822992. DOI:10.1056/NEJMoa055531; Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513(7517):202–9.; Cristescu R., Lee J., Nebozhyn M. et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015;21(5):449–56. PMID: 25894828. DOI:10.1038/nm.3850; Kim J.Y., Shin N.R., Kim A. et al. Microsatellite instability status in gastric cancer: a reappraisal of its clinical significance and relationship with mucin phenotypes. Korean J Pathol 2013;47(1):28–35. PMID: 23483099. DOI:10.4132/KoreanJPathol.2013.47.1.28; Lin J.T., Wu M.S., Shun C.T. et al. Microsatellite instability in gastric carcinoma with special references to histopathology and cancer stages. Eur J Cancer 1995;31a(11):1879–82. PMID: 8541117. DOI:10.1016/0959-8049(95)00349-n; Choi Y.Y., Bae J.M., An J.Y. et al. Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. J Surg Oncol 2014;110(2):129–35. PMID: 24737677. DOI:10.1002/jso.23618; Zhu L., Li Z., Wang Y. et al. Microsatellite instability and survival in gastric cancer: A systematic review and meta-analysis. Mol Clin Oncol 2015;3(3):699–705. PMID: 26137290. DOI:10.3892/mco.2015.506; Sohn B.H., Hwang J.-E., Jang H.-J. et al. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clin Cancer Res 2017;23(15): 4441–9. PMID: 28747339. DOI:10.1158/1078-0432; Choi Y.Y., Kim H., Shin S.-J. et al. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Ann Surg 2019;270(2):309–16. PMID: 29727332. DOI:10.1097/SLA.0000000000002803; Hashimoto T., Kurokawa Y., Takahashi T. et al. Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Gastric Cancer 2019;22(4):785–92. PMID: 30617648. DOI:10.1007/s10120-01800918-4; Smyth E.C., Wotherspoon A., Peckitt C. et al. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol 2017;3(9): 1197–203. PMID: 28241187. DOI:10.1001/jamaoncol.2016.6762; Fuchs C.S., Doi T., Jang R.W. et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018; 4(5):e180013. PMID: 29543932. DOI:10.1001/jamaoncol.2018.0013; Mandard A.M., Dalibard F., Mandard J.C. et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73(11):2680–6. PMID: 8194005. DOI:10.1002/1097-0142(19940601)73:113.0.co;2-c; Ottini L., Falchetti M., Lupi R. et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol 2006;17(Suppl 7):vii97–102. PMID: 16760303. DOI:10.1093/annonc/mdl960; Beghelli S., Manzoni G., Barbi S. et al. Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery 2006;139(3)347–56. PMID: 16546499. DOI:10.1016/j.surg.2005.08.021; Polom K., Marano L., Marrelli D. et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg 2018;105(3):159–67. PMID: 29091259. DOI:10.1002/bjs.10663; Yothers G., O’Connell M.J., Allegra C.J. et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29(28): 3768–74. PMID: 21859995. DOI:10.1200/JCO.2011.36.4539; André T., Boni C., Mounedji-Boudiaf L. et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343–51. PMID: 15175436. DOI:10.1056/NEJMoa032709; Seymour M.T., Morton D. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemo therapy (NAC) for colon cancer. J Clinical Oncology 2019; 37(Suppl 15):3504. DOI:10.1200/JCO.2019.37.15_suppl.3504; Tougeron D., Mouillet G., Trouilloud I. et al. Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study. J Natl Cancer Inst 2016;108(7). PMID: 26839356. DOI:10.1093/jnci/djv438; Kubota Y., Kawazoe A., Sasaki A. et al. The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer. Clin Cancer Res 2020;26(14):3784–90. PMID: 32156744. DOI:10.1158/1078-0432.CCR-20-0075; Tryakin A.A., Fedyanin M.Y., Tsukanov A.S. et. al. Microsatellite instability as a unique characteristic of tumors and a predictor of response to immune therapy. Malignant tumours 2019;9(4): 59–69. DOI:10.18027/2224-5057-2019-9-4-59-69; Zhang Z., Cheng S., Gong J. et al. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series. Eur J Surg Oncol 2020;46(10, Pt B):e33–9. PMID: 32732092. DOI:10.1016/j.ejso.2020.06.034; Al-Batran S.-E., Lorenzen S., Thuss-Patience P.S. et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. Journal of Clinical Oncology 2022;40(Suppl 16):4003.; Andre T., Tougeron D., Piessen G. et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study. J Clinical Oncology 2022;40(Suppl 4):244. PMID: 35969830. DOI:10.1200/JCO.22.00686; Сунь Х., Неред С.Н., Трякин А.А. и др. Неоадъювантная химиоиммунотерапия у пациентов с раком желудка с микросателлитной нестабильностью. Вопросы онкологии 2023;69(2):275–84. DOI:10.37469/0507-3758-2023-69-2-275-284; Lee H.S., Choi S.I., Lee H.K. et al. Distinct clinical features and outcomes of gastric cancers with microsatellite instability. Mod Pathol 2002;15(6):632–40.; An C., Choi I.-S., Yao J.C. et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005;11(2, Pt 1):656–63. PMID: 15701853; Falchetti M., Saieva C., Lupi R. et al. Gastric cancer with highlevel microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. Hum Pathol 2008;39(6):925–32. PMID: 18440592. DOI:10.1016/j.humpath.2007.10.024; Seo H.M., Chang Y.S., Joo S.H. et al. Clinicopathologic characteristics and outcomes of gastric cancers with the MSI-H phenotype. J Surg Oncol 2009;99(3):143–7. PMID: 19117018. DOI:10.1002/jso.21220; Oki E., Kakeji Y., Zhao Y. et al. Chemosensitivity and survival in gastric cancer patients with microsatellite instability. Ann Surg Oncol 2009;16(9):2510–5. PMID: 19565284. DOI:10.1245/s10434-009-0580-8; Corso G., Pedrazzani C., Marrelli D. et al. Correlation of microsatellite instability at multiple loci with long-term survival in advanced gastric carcinoma. Arch Surg 2009;144(8):722–7. PMID: 19687375. DOI:10.1001/archsurg.2009.42; An J.Y., Kim H., Cheong J.-H. et al. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer 2012;131(2):505–11. PMID: 21898388. DOI:10.1002/ijc.26399; Kim S.Y., Choi Y.Y., An J.Y. et al. The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses. Int J Cancer 2015;137(4):819–25. PMID: 25614197. DOI:10.1002/ijc.29449; Marrelli D., Polom K., Pascale V. et al. Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer. Annals of Surgical Oncology 2016:23(3):943–50. PMID: 26530444. DOI:10.1245/s10434-015-4931-3

Availability: https://www.onco-surgery.info/jour/article/view/602
https://doi.org/10.17650/2686-9594-2023-13-2-17-26

Subpopulation structure of tumor-infiltrating lymphocytes in early and locally advanced triple negative breast cancer and its effect on the efficiency of neoadjuvant chemotherapy ; Субпопуляционный состав опухоль-инфильтрирующих лимфоцитов при раннем и местнораспространенном тройном негативном раке молочной железы и его влияние на эффективность неоадъювантной химиотерапии

Authors: M. V. Khoroshilov, E. I. Kovalenko, Е. V. Artamonova, Т. N. Zabotina, I. S. Stilidi, Ya. А. Zhulikov, Е. V. Evdokimova, А. V. Petrovsky, D. А. Denchik, I. К. Vorotnikov, V. N. Sholokhov, S. N. Berdnikov, E. K. Showa, Z. G. Kadagidze, М. В. Хорошилов, Е. И. Коваленко, Е. В. Артамонова, Т. Н. Заботина, И. С. Стилиди, Я. А. Жуликов, Е. В. Евдокимова, А. В. Петровский, Д. А. Денчик, И. К. Воротников, В. Н. Шолохов, С. Н. Бердников, Э. К. Шоуа, З. Г. Кадагидзе

Source: Malignant tumours; Том 13, № 4 (2023); 28-36 ; Злокачественные опухоли; Том 13, № 4 (2023); 28-36 ; 2587-6813 ; 2224-5057

Subject Terms: RCB, neoadjuvant chemotherapy, systemic immunity, tumor-infiltrating lymphocytes, CD8+ PD-1+, NKT, неоадъювантная химиотерапия, системный иммунитет, опухоль-инфильтрирующие лимфоциты, CD8+PD-1+

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1141/797; https://www.malignanttumors.org/jour/article/view/1141/904; Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001 Sep 11;98 (19):10869-74.; Castrellon AB, Pidhorecky I, Valero V et al. The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer. Oncol Rev. 2017 Mar 17;11 (1):324.; Sikov WM, Berry DA, Perou CM et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33 (1):13-21.; Spring LM, Fell G, Arfe A et al. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 Jun 15;26 (12):2838-2848.; O’Meara T.A., Tolaney S.M. Tumor mutational burden as a predictor of immunotherapy response in breast cancer. Oncotarget. 2021; 12: 394-400.; Артамонова Е.В. Роль иммунофенотипирования опухолевых клеток в диагностике и прогнозе рака молочной железы. Автореферат докт. дисс. – Москва. – 2003.; Wang, K. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis / K. Wang, J. Xu, T. Zhang et al. // Oncotarget. –2016. – Vol. 7, N 28. – P. 44288-44298.; Park JH, et al. Prognostic value of tumour-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann. Oncol. 2019; 30:1941–1949.; Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19 (1):40-50.; Loi, S. Tumor-infiltrating lymphocytes and prognosis: A pooled individual patient analysis of early-stage triple-negative breast cancers / S. Loi, D. Drubay, S. Adams et al. // J. Clin. Oncol. 2019. – Vol. 37, N 7. – P. 559-569.; Goda N, Sasada S, Shigematsu H, Masumoto N, Arihiro K, Nishikawa H, Sakaguchi S, Okada M, Kadoya T. The ratio of CD8+ lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer. Discov Oncol. 2022 Apr 19;13 (1):27.; Liu Y, Gao Y, Hao H, Hou T. CD279 mediates the homeostasis and survival of regulatory T cells by enhancing T cell and macrophage interactions. FEBS Open Bio. 2020 Jun;10 (6):1162-1170.; Hu Y, Zhao J, Shen Y, Zhang C, Xia Q, Zhang G, Wang B, Wei B, Yu R, Ma J, Guo Y. Predictive value of tumor-infiltrating lymphocytes detected by flow cytometry in colorectal cancer. Int Immunopharmacol. 2022 Dec;113 (Pt A): 109286.; Заботина Т.Н., Черткова А.И., Борунова А.А., Захарова Е.Н., Шоуа Э.К., Артамонова Е.В., Коваленко Е.И., Хорошилов М.В., Кадагидзе З.Г. Взаимосвязь субпопуляций лимфоцитов больных раком молочной железы с результатами лечения. Российский биотерапевтический журнал. 2021;20 (3):25-33.; Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt R, Harris AL, Old L, Cerundolo V. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol. 2003 Nov 15;171 (10):5140-7.; https://www.malignanttumors.org/jour/article/view/1141

Availability: https://www.malignanttumors.org/jour/article/view/1141
https://doi.org/10.18027/2224-5057-2023-13-4-28-36

Copy number aberrations of DNA BRCA1, NF-κB and PARP1 genes in breast cancer: assotiation with the effect of preoperation chemotherapy and prediction of the disease

Source: Nauchno-prakticheskii zhurnal «Medicinskaia genetika». :10-16

Subject Terms: микроматричные исследования, copy number aberrations, BRCA1, PARP1, NF-κB, 3. Good health, microarray studies, 03 medical and health sciences, 0302 clinical medicine, breast cancer, прогноз, аберрации числа копий, prognosis, рак молочной железы, neoadjuvant chemotherapy, неоадъювантная химиотерапия

Access URL: https://www.medgen-journal.ru/jour/article/download/696/431